Panion & Bf BiotechTPE:1760 +4.60%73 Net Margin % is 8.90% as of Dec. 2025, which is 18% above its 10-year median of 7.54. GuruFocus rates TPE:1760 with a GF Score™ of 73/100 and a GF Value™ of NT$96.01 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 957 Drug Manufacturers companies, Panion & Bf Biotech ranks better than 61.02% on this metric.
The historical rank and industry rank for Panion & Bf Biotech's Net Margin % or its related term are showing as below:
TPE:1760'
s Net Margin % Range Over the Past 10 Years
Min: 1.78 Med: 7.54 Max: 11.3
Current: 9.22
TPE:1760's Net Margin % is ranked better than 61.02% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs TPE:1760: 9.22
Panion & Bf Biotech (TPE:1760) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Panion & Bf Biotech Net Margin % Related Terms
Panion & Bf Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1760 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panion & Bf Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panion & Bf Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a Net Margin % of 8.90% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Panion & Bf Biotech and its competitors. This is 18% above median its historical median of 7.54. Over the past decade, Panion & Bf Biotech's Net Margin % has ranged from 1.78 to 11.30. According to the industry distribution chart, Panion & Bf Biotech ranks #373 out of 957 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Panion & Bf Biotech's Net Margin % too high?
Panion & Bf Biotech's current Net Margin % of 8.90% is 18% above median its 10-year median of 7.54. Over the past 10 years, this metric has ranged from a low of 1.78 to a high of 11.30. The Drug Manufacturers industry median Net Margin % is 5.58. Panion & Bf Biotech's value of 8.90% is 59.5% above this industry median. Based on the distribution chart, Panion & Bf Biotech ranks #373 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Net Margin % compare to VRTX and REGN?
According to the Drug Manufacturers industry distribution chart, Panion & Bf Biotech ranks #373 out of 957 companies for Net Margin %. This puts Panion & Bf Biotech in the upper half of its industry. The industry median Net Margin % is 5.58. Panion & Bf Biotech's value of 8.90% is 59.5% above this benchmark. Historically, Panion & Bf Biotech's own Net Margin % has ranged from 1.78 to 11.30 over the past decade. While the company's 10-year median is 7.54 vs. the industry median of 5.58, Panion & Bf Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panion & Bf Biotech's current Net Margin % of 8.90% is 59.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Panion & Bf Biotech and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current Net Margin % is 8.90%, which is 18% above median its own 10-year median of 7.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$96.01, compared to a current price of NT$65.90 — trading 31.4% below its estimated fair value. The current Net Margin % is 8.90%, which is 18% above median its 10-year median of 7.54 and 59.5% above the Drug Manufacturers industry median of 5.58. Panion & Bf Biotech's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Net Margin % is 8.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$65.90 is trading 31.4% below its estimated GF Value™ of NT$96.01.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
Net Margin %: 8.90% (18% above median its 10-year median of 7.54)
GF Value™: NT$96.01 vs. price of NT$65.90 (31.4% below fair value)
Industry Position: 59.5% above the Drug Manufacturers median (#373 of 957)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
73GF Score
Get the complete analysis for TPE:1760
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
